Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies

Oncology Reports

Volumn 17, Issue 6, 2007, Pages 1429-1435

  Okita, Riki ^a   Yamaguchi, Yoshiyuki ^a   Emi, Akiko ^a   Matsuura, Kazuo ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Adoptive immuno therapy; Carboxyfluorescein diacetate succinimidyl ester; CD25; Cell line; Cytotoxic T lymphocyte associated antigen 4; FOXP3; Gastric cancer; Lymphokine activated killer cell; Regulatory T cell

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; METABOLISM; NEOPLASM; PHENOTYPE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHENOTYPE;

EID: 34548016111     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.6.1429     Document Type: Article

References (30)

1. Rosenberg SA, Lotze MT, Muul LM, et al: Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985. (Pubitemid 16212345)
2. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680, 1988. (Pubitemid 19015247)
3. Aruga A, Yamauchi K, Takasaki K, et al: Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Int J Cancer 49: 19-24, 1991.
4. Kono K, Takahashi A, Sugai H, et al : Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8: 3394-3400, 2002. (Pubitemid 35340713)
5. Boczkowski D, Nair SK, Synder D, et al: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472, 1996. (Pubitemid 26324100)
6. Yamaguchi Y, Ohshita A, Kawabuchi Y, et al: Adoptive immunotherapy of cancer using activated autologous lymphocytes - current status and new strategies. Hum Cell 16: 183-189, 2003.
7. Marincola FM, Jaffee EM, Hicklin DJ and Ferrone S: Escape of human solid tumors from T-cell recognition, molecular mechanisms and functional significance. Adv Immunol 74: 181-273, 2000.
8. Lou Y, Vitalis TZ, Basha G, et al: Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 65: 7926-7933, 2005. (Pubitemid 41297271)
9. Salvucci O, Kolb JP, Dugas B, Dugas N and Chouaib S: The induction of nitric oxide by interleukin-12 and tumor necrosis factor-α in human natural killer cells, relationship with the regulation of lytic activity. Blood 92: 2093-2102, 1998. (Pubitemid 28446699)
10. Smyth MJ, Thia KY, Street SE, et al: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191: 661-668, 2000.
11. Kato Y, Tanaka Y, Miyagawa F, Yamashita S and Minato N: Targeting of tumor sells for human γδ T cell by non-peptide antigens. J Immunol 167: 5092-5098, 2001. (Pubitemid 33009743)
12. Wolf AM, Wolf D, Steurer M, et al: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612, 2003. (Pubitemid 36182591)
13. Ichihara F, Kono K, Takahashi A, et al: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404-4408, 2003. (Pubitemid 37248397)
14. +regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14: 1269-1273, 2005.
15. Sakaguchi S, Sakaguchi N, Asano M, et al: Immunologic self-tolerance maintained activated T cells expressing IL-2 receptor α-chains (CD25), breakdown of a single mechanism of self-tolerance caused various autoimmune diseases. J Immunol 155: 1151-1164, 1995.
16. Read S, Malmstrom V and Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192: 295-302, 2000. (Pubitemid 30470312)
17. Akagi M, Yokozaki H, Kitadai Y, et al : Expression of amphiregulin in human gastric cancer cell lines. Cancer 75: 1460-1466, 1995.
18. Augulo R and Fulcher DA: Measurement of Candida-specific blastogenesis, comparison of carboxyfluorescein succinimidyi ester labeling of T cell, Thymidine incorporation and CD69 expression. Cytometry 34: 143-151, 1998.
19. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005. (Pubitemid 46218728)
20. +T cells, a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
21. Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor FOXP3. Science 299: 1057-1061, 2003. (Pubitemid 36222930)
22. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377, 2003. (Pubitemid 36842552)
23. Dannull J, Su Z, Rizzieri D, et al: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633, 2005. (Pubitemid 43121851)
24. Allouche M, Sahraoui Y, Augery-Bourget Y, et al: Interleukin 2 receptors. Leuk Res 14: 699-703, 1990. (Pubitemid 20244861)
25. Kudo-Saito C, Schlom J, Camphausen K, et al: The requirement of multimodal therapy (vaccine, local tumor radiation and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 11: 4533-4544, 2005. (Pubitemid 40825644)
26. +T regulatory cells. J Immunol 176: 3301-3305, 2006.
27. +T cell suppressor function. J Immunol 172: 6519-6523, 2004.
28. Waterhouse P, Penninger JM, Timms E, et al : Lymphoproliferative disorders with early lethality in. mice deficient in Ctla-4. Science 270: 985-988, 1995.
29. +immuno- regulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287-296, 1998.
30. +T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 4: 65-78, 2004.